Pri­vate Dan­ish iron de­fi­cien­cy biotech to buy G1 Ther­a­peu­tics for $405M

A decades-old, rel­a­tive­ly un­known pri­vate biotech fo­cused on iron de­fi­cien­cy is buy­ing a com­mer­cial-stage on­col­o­gy com­pa­ny nes­tled in North Car­oli­na.

Hol­bæk, Den­mark-head­quar­tered Phar­ma­cos­mos will ac­quire …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER